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INTRODUCTION
The heterogeneous nature of tumors dramatically complicates the successful treatment of cancer (Meacham and Morrison, 2013) . Tumors display intratumoral heterogeneity as a consequence of genetic differences between individual cells. Together with the diverging microenvironment surrounding tumor cells, this leads to intercellular differences in epigenetic profiles and, subsequently, to differential cellular behavior (Bissell and Hines, 2011; Postovit et al., 2006) . The tumor microenvironment consists of cells, soluble factors such as growth factors, and nonsoluble factors, including the extracellular matrix (Joyce and Pollard, 2009) . A growing number of studies suggest that extracellular vesicles (EVs) may also be an important microenvironmental factor (Raposo and Stoorvogel, 2013 ) that could potentially affect tumor heterogeneity. Many different cell types have been shown to transfer biomolecules, including proteins, lipids, and nucleic acids, through the release and uptake of EVs (Raposo and Stoorvogel, 2013) . In vitro assays showed that EV cargo, such as mRNA, is functional in cells that take up EVs (Valadi et al., 2007) , leading to behavioral changes of recipient cells (Ratajczak et al., 2006; Salomon et al., 2013) . Tumor cells also release a wide variety of EVs (Bobrie and Thé ry, 2013; Thé ry et al., 2009) , the cargo of which can potentially be used as biomarkers (Balaj et al., 2011; D'Souza-Schorey and Clancy, 2012; Skog et al., 2008) . The cargo of EVs isolated from tumor cell culture media can be bioactive because injection of concentrated tumor-cell-line-derived EVs educates tumorsupporting cells, such as bone-marrow-derived cells, that subsequently prepare sentinel lymph nodes and lungs for metastasis (Hood et al., 2011; Peinado et al., 2012) . Vice versa, EVs from stromal cells-for example, fibroblasts and activated T cells-have been shown to alter the protrusive and migratory behavior of tumor cells (Cai et al., 2012; Luga et al., 2012) .
EV exchange between tumor cells in heterogeneous tumors could potentially dramatically accelerate tumor progression if highly metastatic cells spread their malignant behavior to less malignant cells. However, acquiring direct evidence for the exchange of active biomolecules between tumor cells in vivo so far remained challenging due to many technical limitations (Raposo and Stoorvogel, 2013; Thé ry, 2011) . First, in vivo tumor cells are exposed to EVs released by various cell types, making it impossible to specifically measure the effect of tumor-derived EVs on other tumor cells. To address this, concentrated EV preparations isolated from cancer cell culture supernatants have been injected into animal models. However, this does not reflect the location, concentration, and continuous nature of EV release by tumor cells in their in vivo setting. Second, techniques have been lacking to directly track and study cells that take up invivo-released tumor EVs and to compare their behavior to counterparts that did not take up tumor-released EVs. Therefore, it is unknown whether, in heterogeneous tumors in living mice, cells with high metastatic potential can transfer biomaterial to less metastatic cells, thereby influencing tumor progression.
Here, we combine high-resolution intravital imaging with a Cre recombinase-based method to study EV exchange between tumor cells. To show the spread of metastatic behavior through EVs in living mice, we directly visualized the release of EVs by highly metastatic human MDA-MB-231 mammary tumor cells. Moreover, in living mice, we identified and studied the behavior of less malignant human T47D mammary tumor cells that take up these in-vivo-released EVs by more malignant MDA-MB-231 cells. Our study illustrates that tumor heterogeneity contains an additional layer of complexity with tumor cells sharing biomolecules through local and systemic transfer of EVs, which profoundly affects cell behavior.
RESULTS AND DISCUSSION

Tumor Cells Release a Heterogeneous Population of EVs In Vivo
To examine the in vivo release of EVs by highly metastatic tumor cells, we orthotopically transplanted MDA-MB-231 cells in the mammary glands of mice, leading to the formation of highly metastatic mammary tumors. Next, we examined sections of these tumors using confocal microscopy. As expected, we observed EVs with a wide variety of sizes ( Figure 1A) . Next, to further analyze the in vivo release of these EVs, we intravitally imaged similar mammary tumors consisting of differently labeled MDA-MB-231 cells ( Figure 1B) . We observed the release of EVs with a diameter of 2.5 mm and smaller ( Figure 1B and Movie S1, S2, and S3). Because the resolution of a multiphoton microscope is one order of magnitude smaller than the size of EVs such as exosomes ($500 versus 50 nm, respectively), the signal of small EVs will be blurred to an area according to the microscope's point spread function (>1 mm diameter). To characterize the heterogeneous mixture of EVs, including plasma membrane-shed vesicles and exosomes, we isolated EVs from MDA-MB-231 tumors as confirmed by electron microscopy ( Figure 1C ) and determined the size distribution by nanoparticle tracking analysis (NanoSight) ( Figure 1D ). Next, to identify potentially functional EV cargo, we took the cells and EVs from tumors and isolated their mRNA. We identified the differential mRNA profile using gene expression arrays ( Figure 1E ) and found a significant enrichment of mRNA molecules from >200 genes in EVs compared to the cells (red dots Figure 1E and Table S1 ). Gene ontology analysis showed that many of these enriched mRNA molecules are involved in migration and metastasis (indicated in red in Figure 1F and Table S2 ), both of which promote tumor progression. Which mRNAs carried by EVs are critical for induction of behavioral changes of recipient cells depends on the expression profile of the recipient cell. The mRNAs enriched in EVs released by MDA-MB-231 cells may change the behavior of MDA-MB-231 cells that take up these EVs due to the abundance of mRNAs involved in metastasis. However, mRNAs from MDA-MB-231 cells that are not vesicular enriched but abundantly present may induce behavioral changes when the mRNA level of those particular genes is low in other recipient cell types. This also holds true for other potentially functional biomolecules loaded in EVs such as DNA, (signaling) proteins, lipids, and microRNAs (Raposo and Stoorvogel, 2013) . Therefore, it is important to realize that our data do not point to individual biomolecules that induce phenotypic changes in recipient cells but illustrate that, within the tumor microenvironment, a heterogeneous population of EVs is present containing biomolecules, among which there are mRNAs that are involved in migration and metastasis.
The Cre/LoxP System Can Be Used to Study EV Uptake To study EV exchange in vivo, we utilized the Cre-LoxP system to induce a color switch specifically in reporter-expressing cells (reporter + ) that take up EVs released from cells expressing the Cre recombinase (Cre) (Cre + cells) ( Figure 2A ). This Cre-LoxP system uses the reverse approach of rendering donor cells vesiculation deficient; recipient cells that do not take up EVs are marked with DsRed (i.e., unrecombined reporter) and serve as an internal control for eGFP-expressing recipient cells that have taken up EVs. Importantly, the detection is restricted to uptake of EVs released by Cre + cells. This enables the analysis of biological effects induced by EVs released from an a priori defined tumor cell population in vivo.
To study EV exchange using the Cre-LoxP system, we generated a MDA-MB-231 cell line expressing CFP and Cre. We isolated EVs released from this Cre + cell line, as confirmed by electron microscopy ( Figure 2B ), and determined their size distribution ( Figure 2C ). Importantly, tumor cells were able to take up purified and fluorescently labeled EVs in vitro ( Figure 2D and Movie S4). Next, by western blot analysis, we confirmed that the EVs contained the typical EV markers CD63 and Hsp70. Although Cre protein was undetectable ( Figure 2E ) in EVs, Cre mRNA was readily detected by RT-PCR ( Figure 2F Figure 3D , bottom). To study whether malignant MDA-MB-231 cells can also transfer Cre to other, less malignant, tumor cells, we generated T47D and MCF-7 reporter + cells. Interestingly, Cre was also transferred from malignant to these less malignant cells in a cell-cell contact-independent manner ( Figure 3D , middle and right) and concentration-dependent manner ( Figure 3E ). These data suggest that, in vitro, tumor cells with a high metastatic potential can functionally transfer biomolecules (e.g., Cre) to less malignant cells that could potentially affect their physiology.
Tumor Cells Take Up Tumor-Cell-Derived Cre + EVs
In Vivo Next, we used the Cre-LoxP system to investigate the in vivo existence of cell-to-cell transfer of mRNA and other biomolecules (Wang et al., 2013) . Bar plot representation of p values from a gene ontology enrichment analysis. Biological processes involved in cell movement are shown in red. See also Movies S1, S2, and S3 and Tables S1  and S2. in different mammary and melanoma tumor models (Figures 4 and S1). We confirmed that EVs isolated from Cre + tumors contained Cre mRNA ( Figure 4A ). Next, we pretreated these EVs with RNase and proteinase K (to degrade free-floating Cre RNA and Cre protein) and showed that, upon intratumoral injection, reporter + cells take up these EVs and report Cre activity ( Figure 4B ). Thus, cells only report vesicular Cre, which is further supported by our observation that cells do not report the uptake of free-floating Cre upon injection of recombinant Cre protein ( Figure 4C ) or whole-cell lysate of a Cre + tumor ( Figure 4D ). Interestingly, similar to our in vitro observations, in all mammary and melanoma tumor models that we studied, eGFP + reporter + cells (negative for CFP [ Figure S2 ]) appeared in tumors consisting of Cre + cells and reporter + cells ( Figure 4E and see Movie S5 for a 3D reconstruction of a z stack of intravital images). Combined, these data suggest that in vivo tumor cells can release and take up EVs and that the functional mRNA transfer via EVs can be reported by the Cre-LoxP system.
EV Exchange between Tumor Cells and Non-Tumor Cell Types
Our Cre-Lox reporter enables us to study the uptake of EVs released by defined populations of cells. Therefore, in our in vivo syngeneic melanoma tumor model, we tested whether different types of non-tumor cells take up tumor-released EVs and whether tumor cells can take up EVs released from non-tumor cells. We generated Cre-expressing B16 melanoma cells and injected these cells into mice ubiquitously expressing the Cre-LoxP reporter tdTomato (tdTomato B6 mice) ( Figure 5A ). Within 2 weeks, these mice developed palpable tumors, and we examined various tissues for the presence of different types of non-tumor cells that report the uptake of Cre (i.e., tdTomato expression). Interestingly, we observed non-tumor cells expressing tdTomato in all examined tissues (tumors, lymph nodes, lungs, and spleens) ( Figure 5B ). To investigate the nature of these cells, we analyzed the expression of different markers, including CD45, which is a general immune cell marker. Interestingly, we observed CD45 À and CD45 + cells, suggesting that both non-immune cells and immune cells have taken up tumorreleased EVs ( Figure 5C ). By immunohistochemistry, we identified various cell types, including Gr1 + cells and F4/80 + cells, suggesting the transfer of tumor-released EVs to neutrophils and macrophages ( Figure 5D ). From this, we conclude that not only tumor cells but also multiple non-tumor cell types are able to take up tumor cell-released EVs.
To test whether tumor cells can take up EVs released from non-tumor cells, we generated B16 melanoma cells that express the Cre-LoxP reporter as shown in Figure 2A . Next, we injected these reporter cells into B6 mice in which Cre is ubiquitously expressed by the ACTB promoter ( Figure 5E ). Within 2 weeks, these mice developed palpable tumors that we examined for the presence of tumor cells reporting the uptake of EVs released by Cre-expressing non-tumor cells. Only occasionally (2 ± 0.7 cells per mm 3 ; n = 3 mice), we observed tumor cells that report the uptake of EVs released from non-tumor cells ( Figure 5F ). This observation is in line with the general assumption that non-tumor cells release relatively less EVs compared to tumor Data are represented as mean ± SEM.
cells (Balaj et al., 2011; Raposo and Stoorvogel, 2013 Figure 6B, right) . As expected, systemic transfer of Cre activity was less efficient than local transfer (Figure 6C) . However, the observed efficiency in local transfer presumably represents an underestimation of the actual transfer because Cre-reporting efficiency depends on the ratio of Cre + Figure S3 ). In this model, we did not observe any Cre + MCF-7 cells in the contralateral T47D reporter + tumors (n = 4 mice), whereas T47D reporter + cells report the uptake of EVs released by the MCF-7 cells located at the contralateral side ( Figure S3A ). Thus, both in in vitro culture models and in living mice, tumor cells release and exchange functional biomolecules (e.g., Cre) locally and systemically through EVs.
Migration of T47D Cells Is Enhanced upon Uptake of MDA-MB-231-Derived EVs
Because we found mRNAs from many genes involved in migration and metastasis in MDA-MB-231-isolated EVs ( Figure 1F ) and in vitro data have shown that mRNA can be functionally transferred to other cells (Valadi et al., 2007 ) (as we confirmed in vivo for Cre), we investigated whether these EVs can affect the migra- Figure 6A ). We tracked the migration of all individual eGFP + cells and randomly picked proximate DsRed + cells within the same imaging field (Figure 6D) and measured the average migration speed of these cells per imaging field ( Figure 6E, Figure 6E ) than when MDA-MB-231 cells were located in a distant tumor (distant communication; Figure 6F ).
In order to test how the transfer of biomolecules, as reported by our Cre reporter, affects migration within one space-confined microenvironment, we compared the migration of eGFP + and eGFP + and DsRed + cells illustrates the effect of EV uptake. In all 18 distinct positions reporting local transfer (n = 3 mice) (Figure 6E ) and in 15 of the 17 distinct positions reporting systemic transfer (n = 3 mice) ( Figure 6F ), we observed that eGFP + cells are more migratory than neighboring DsRed + cells. To quantify this effect within the various microenvironments, we normalized the migration distance of tumor cells to the average migration path of DsRed + cells that did not report Cre activity in each imaging field independently (Figures 6G and 6H ). Over time, we tracked the position of more than 360 cells per condition (n = 3 mice) and found that eGFP + cells migrate 1.57 ± 0.084 ( Figure 6G ) and 2.37 ± 0.431 ( Figure 6H ) times faster than the DsRed + cells after local and distant communication, respectively. Similar results were found in in vitro studies in which we imaged local (co-culture) and distant (transwell) communication ( Figures  S4A and S4B ). The observed effects on migration were not due to the expression of the different fluorophores because cells that became eGFP + upon transfection with a Cre-encoding DNA plasmid did not migrate faster than DsRed + cells (Figure S4C ). Our data suggest that tumor cell migration is dependent on non-systemic cues in the local microenvironment and that this migration can be significantly enhanced by the uptake of migration-associated mRNAs through EV transmission. The correlation between Cre uptake and increased motility is fully consistent with the migratory-inducing mRNA cargo that we identified in MDA-MB-231-released EVs, unless motile cells are somehow more prone to take up biomolecules than lessmotile cells. Several lines of evidence exclude the latter hypothesis. First, within one cell line (MDA-MB-231), the fast-migratory cells did not take up more fluorescently labeled EVs than slow-migratory cells ( Figure S5A ). Second, if motile cells would have a higher a priori propensity to report Cre activity, then eGFP + cells would always migrate faster than DsRed + cells, which was not observed when comparing the migration speed of eGFP + and DsRed + cells across different imaging fields (Figures 6E and 6F) . Third, the percentage of cells that report Cre was not increased in imaging fields with migratory-supporting microenvironments where faster average migration was observed ( Figure S5B ). Fourth, the uptake of EVs produced by a less migratory cell line (MCF-7) ( Figure S3B ) did not lead to enhanced migration of eGFP + cells; instead, we observed a significant decrease in migration ( Figure S3C ). Therefore, our data collectively show that migration of T47D cells is enhanced upon the uptake of EVs released by MDA-MB-231 cells.
T47D Cells that Take Up MDA-MB-231 EVs Become More Metastatic
Because activating migration and invasion is one of the hallmarks of cancer Weinberg, 2000, 2011) and key to metastasis (Nguyen et al., 2009) , the transfer of biomolecules, including mRNAs involved in migration, may affect not only the migratory behavior but also the metastatic potential of tumor cells. To investigate this, we isolated the lungs of four mice and analyzed in total >1,000 metastases ( Figure 7A ). When the potential to metastasize to the lungs is enhanced by EV uptake in the population of cells that report Cre activity (eGFP + ), the ratio of eGFP + over DsRed + cells that arrive and grow out in the lung is expected to be increased compared to the ratio of these populations of cells in the corresponding primary tumor ( Figure 7A ). As expected, T47D cells that take up EVs released by less migratory MCF-7 cells ( Figure S3B ) did not show an increase in metastatic potential ( Figure S3D ). Strikingly, when we analyzed the lungs and corresponding primary tumors of malignant MDA-MB-231 and less malignant T47D cells ( Figures 7B and 7C) , we observed that T47D cells that take up EVs released by the more malignant MDA-MB-231 cells showed a 52-fold increase in metastatic potential (i.e., 52-fold increase in the eGFP + over DsRed + ratio in lungs compared to the ratio in corresponding primary tumors) upon local communication ( Figure 7B ) and a 7.9-fold increase upon distant communication ( Figure 7C ). In addition to the less malignant T47D cells, MDA-MB-231 themselves also showed enhanced migration and metastasis upon uptake of EVs released by MDA-MB-231 cells ( Figure S6 ), which is not surprising because mRNAs involved in metastasis were specifically loaded and enriched in EVs, and therefore, cells that take up these EVs are exposed to higher levels of mRNAs involved in metastasis. These data combined suggest that the uptake of these vesicular mRNA molecules boosts both migration and metastatic potential of tumor cells.
Concluding Remarks
In this manuscript, we presented a technique to visualize EV transfer between tumor cells both in vitro and in living mice based on the Cre-LoxP system and study the physiological effects of this transfer. Others have tried to study the functional role of EV-mediated cell-cell communication in vivo by inhibiting multivesicular body-related EV pathways in order to render cells vesiculation deficient. However, this only led to a partial reduction in EV production (Bobrie et al., 2012; Peinado et al., 2012) , probably because EV shedding from the plasma membrane was unaffected. More importantly, manipulating the EV-producing cells, by any means, may not only affect EV production, but also EV-independent factors (e.g., the cytokine profile of donor cells as observed for osteopontin, PIGF-2, PDGF-AA [Peinado et al., 2012] ) with EV-independent effects on migration and metastasis of recipients cells. We took an alternative and reverse approach by using the Cre-LoxP system where the behavior of eGFP + tumor cells (i.e., that have taken up tumor-EVs) is compared to the behavior of DsRed + tumor cells. The observed differential behavior illustrates how uptake of EVs released from Cre + cells affects recipient cells without the requirement to manipulate EV-releasing cells. An additional advantage of the Cre-LoxP system is that it allows detection of uptake of only the EVs released from an a priori defined cell population. Using this method, we showed directional transfer of biomolecules between tumor cells and also between tumor and non-tumor cells ( Figure 5 ). The latter observation is in line with previous findings that bone-marrow-derived cells that take up EVs can promote metastatic niche formation (Peinado et al., 2012) .
As with any technique, the Cre-LoxP system also has downsides. First, a small fraction of the Cre exchange that we detected may have occurred via EV-independent mechanisms, despite that we excluded cell-cell fusion and Cre transfer through direct cell-cell contact and despite that we observed only color switching upon intratumoral injection of purified Cre + EVs and not upon injection of non-vesicular free Cre. Second, the functional transfer of Cre does not identify the exact functional biomolecules that are transferred. Although we found a set of enriched mRNAs of genes involved in migration and metastasis, our Cre-LoxP system only reports EV uptake and does not specify transfer of any type of functional biomolecules such as DNA, (signaling) proteins, lipids, and microRNAs.
We found the mRNA of >200 genes to be vesicular enriched compared to the MDA-MB-231 cells that release these EVs. The enrichment of these biomolecules can be explained by specific loading (e.g., Villarroya-Beltri et al., 2013) or by non-specific loading of biomolecules located at peripheral cell region in EVs that are released at the edge of cells. The transfer of metastatic capacity as reported by our Cre-LoxP system is therefore likely to be caused by the transfer of multiple specifically and non-specifically loaded functional biomolecules, such as DNA, (signaling) proteins, lipids, microRNAs, and mRNAs that concertedly affect the multiple parallel migration and metastasis pathways. The molecules responsible for phenotypic switches in recipient cells cannot be generalized; different recipient cell types with expression profiles that differ from the EV-producing cells may also get affected by biomolecules that are abundantly present but not necessarily enriched in EVs. Therefore, the vesicular mRNA from the genes listed in Figure 1F affect MDA-MB-231 cells, whereas mRNA from yet another set of genes loaded in the same EVs may alter the behavior of other cell types.
Our study provides evidence in the physiological context of heterogeneous tumors inside whole organisms that tumor cells take up in-vivo-released tumor EVs. The provided proof here for the existence of EV transfer between tumor cells with a role in tumor progression is supported by in vitro studies (Al-Nedawi et al., 2008; Demory Beckler et al., 2013; Higginbotham et al., 2011; O'Brien et al., 2013; Skog et al., 2008) . We demonstrate, in living mice, that malignant tumor cells, through transfer of EVs, enhance the migratory behavior and metastatic capacity of less malignant cells. These data exemplify that tumor heterogeneity is much more complex than currently anticipated, which has profound consequences for our ideas on the mechanisms of tumor progression and for designing optimal treatment strategies. EV-mediated long-range cell-cell communication could indicate that metastasized cells may influence the metastatic capacity of less malignant tumor cells in the primary tumor and that tumor cells that have acquired resistance to chemotherapy may influence the therapy resistance of other tumor cells. However, more detailed future studies are required, especially in a clinical setting, before the full magnitude and clinical implications of our observations can be revealed.
EXPERIMENTAL PROCEDURES
Intravital Imaging
Mice were sedated using isoflurane inhalation anesthesia (1.5% to 2% isoflurane/O 2 mixture). The imaging site was surgically exposed, and the mouse was placed with its head in a facemask within a custom-designed imaging box. The isoflurane was introduced through the facemask and ventilated by an outlet on the other side of the box. The imaging box and microscope were kept at 36.5 C by a climate chamber that surrounds the whole stage of the microscope, including the objectives. Imaging was performed on an inverted Leica TCS SP5 AOBS multi-photon microscope (Mannheim, Germany) with a chameleon Ti:Sapphire pumped Optical Parametric Oscillator (Coherent Inc.). The microscope is equipped with four non-descanned detectors: NDD1 (<455 nm), NDD2 (455-490 nm), NDD3 (500-550 nm), and NDD4 (560-650 nm). Different wavelengths between 700 nm and 1,150 nm were used for excitation; CFP was excited with a wavelength of 840 nm, and GFP and DsRed were excited with a wavelength of 960 nm. CFP was detected in NND2, GFP was detected in NDD3, and DsRed was detected in NDD4. All images were in 12 bit and acquired with a 253 (HCX IRAPO N.A. 0.95 WD 2.5 mm) water objective. All pictures were processed using ImageJ software; pictures were converted to an 8 bit RGB, smoothed (if necessary), cropped (if necessary), rotated (if necessary), and contrasted linearly.
Tracking Migration of Tumor Cells
The eGFP and DsRed images of tumors were acquired in living mice using our multi-photon microscope. Individual DsRed + and eGFP + cells can be recognized equally well, and migration differences caused by detection differences can thus be excluded. Three-dimensional volumes (z stacks) were collected, and the images were stored on the hard-disk for analysis. Images were corrected for XYZ-drift using custom-made software. Cells were tracked manually with an ImageJ plugin (''Manual Tracking'' Rasband, W.S., ImageJ, U.S. NIH; http://imagej.nih.gov/ij/). At the beginning of each movie, a random DsRed + cell close to an eGFP + cell was selected. The XY position was determined over time, and the displacement and track distance were calculated by Excel (Microsoft).
Analyzing Metastatic Capacity of Tumor Cells
Cryosections (150 mm thick) of tumors and lungs were prepared and imaged as described in the Extended Experimental Procedures section ''Immunostainings and Confocal Microscopy of Tissue Sections.'' The images were coded randomly by one investigator, and the images were blinded analyzed by two independent researchers that did not know the experimental conditions. Tile scans of tumors were analyzed using ImageJ; a binary threshold was set separately for the red and green channels, the number of pixels above the threshold (being positive for either red or green) was measured, and the ratio eGFP/DsRed was determined. Tile scans of lungs were analyzed in LAS-AF; the amount of DsRed + and eGFP + metastases was counted manually, and the ratio eGFP/DsRed was determined. We classified metastases into two categories; metastases that were entirely DsRed + and metastases that were entirely eGFP + . Only a few metastases (< 2.5%) were multicolored and therefore excluded from our analysis. Metastatic potential is calculated by dividing the ratio of eGFP + over DsRed + cells that arrive and grow out in the lung by the ratio of these populations of cells in the primary tumor.
Gene Expression Analysis
Total RNA was isolated from cells and EVs using the TRIZOL reagent according to the manufacturer's instructions (Invitrogen) and quantified using a ND1000 spectrophotometer (Nanodrop Technologies). The quality control, RNA labeling, hybridization, and data extraction were performed at ServiceXS B.V. The RNA quality and integrity were determined using Labon-Chip analysis on the Agilent 2100 Bioanalyzer (Agilent Technologies, Inc.). Biotinylated cRNA was prepared using the Illumina TotalPrep RNA Amplification Kit (Ambion, Inc.) according to the manufacturer's specifications with an input of 200 ng total RNA. Per sample, 750 ng of the obtained biotinylated cRNA samples was hybridized onto the Illumina HumanHT-12 v4 (Illumina, Inc.). Each BeadChip contains 12 arrays. Hybridization and washing were performed according to the Illumina Manual ''Direct Hybridization Assay Guide.'' Scanning was performed on the Illumina iScan (Illumina, Inc.). Image analysis and extraction of raw expression data were performed with Illumina GenomeStudio v2011.1 Gene Expression software with default settings (no background subtraction and no normalization). Primary gene expression analysis of the scanned BeadChip arrays was performed using Illumina's GenomeStudio v.2011.1 software with the default settings advised by Illumina. The data were analyzed with the R/Bioconductor package limma (Wang et al., 2013) . To remove non-linear hybridization artifacts, we first performed loess normalization. Next, we combined replicates to calculate p values for differential expression. Finally, we took a 2-fold cut-off to select only the most strongly enriched RNAs in the vesicles compared to whole-cell RNA. The set of enriched genes was analyzed using the WebGestalt tool for functional classification. The set of enriched RNAs was used as the input set; the genes present on the array were used as a background set. The data discussed in this publication have been deposited in NCBI's Gene Expression Omnibus (Edgar et al., 2002) and are accessible through GEO series accession number GEO: GSE66488 (http://www.ncbi.nlm.nih.gov/geo/query/acc. cgi?acc=GSE66488).
Statistical Analyses
For all normal distributed measurements, the Student's t test was used to determine whether there was a significant difference between two means (p < 0.05), and for all others the Mann-Whitney U test was used. Significance is marked with one asterisk when the p value is equal to or smaller than 0.05, and with two asterisks when the p value is equal to or smaller than 0.01. Supplemental Experimental Procedures are available in the Supplemental Information section.
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